Prognostic value of pentraxin 3 in patients with chronic heart failure.

Abstract

BACKGROUND:

A long pentraxin, PTX3, is produced by vascular cells or inflammatory cells and released into the circulation, possibly reflecting local inflammation in the cardiovascular system.

AIM:

This study was designed to assess the clinical significance of plasma pentraxin 3 (PTX3) levels in chronic heart failure (CHF).

METHODS:

We measured plasma PTX3 levels in 37 patients with non-ischemic CHF (dilated cardiomyopathy) using enzyme-linked immunosorbent assay (ELISA) methods.

RESULTS:

The plasma PTX3 levels were higher in CHF patients than in healthy subjects (P=0.001), and the CHF patients in the highest tertile of plasma PTX3 levels had more cardiac events than the patients in the lowest tertile (42% vs. 0%, P=0.02). Multivariate regression analysis showed that PTX3 was the most significant predictor of cardiac events (hazard ratio 1.912 for each increase in PTX3 of 1 ng/ml, P=0.019, 95% CI 1.114-3.282). In addition, PTX3 was strikingly expressed in human myocardial cells obtained from a biopsy specimen in a patient.

CONCLUSION:

Plasma PTX3 levels might be a potentially useful biomarker to predict prognosis as well as to detect inflammatory status in patients with CHF.

• Authors: Norihiko Kotooka, Teruo Inoue, Shigehisa Aoki, Mayumi Anan, Hiroshi Komoda, Koichi Node
• Journal: International journal of cardiology (Int J Cardiol) Vol. 130 Issue 1 Pg. 19-22 (Oct 30 2008) ISSN: 1874-1754 [Electronic] Netherlands
• PMID: 18045709 (Publication Type: Journal Article)

Chemical References

• Serum Amyloid P-Component
• PTX3 protein
• C-Reactive Protein

Topics

• C-Reactive Protein (analysis)
• Chronic Disease
• Heart Failure (blood)
• Humans
• Prognosis
• Serum Amyloid P-Component (analysis)